Description

PDS-MMAE (Compound 5’) is a modified MMAE (HY-15162). PDS-MMAE can be used for preparation of neurotensin receptor binding conjugates[1].-4°C (Powder, protect from light)-Applications-Cancer-programmed cell death-Formula-C47H74N6O9S2-Citation–References-[1]Mark T. Bilodeau, et al. Neurotensin receptor binding conjugates and formulations thereof. Patent. WO2017180834.-CASNumber-1613113-44-2-MolecularWeight-931.26-Compound Purity-99.76-SMILES-C[C@@H](C(N[C@H](C)[C@H](C1=CC=CC=C1)O)=O)[C@H]([C@@](CCC2)([H])N2C(C[C@@H](OC)[C@H]([C@@H](C)CC)N(C)C([C@H](C(C)C)NC([C@H](C(C)C)N(C)C(OCCSSC3=CC=CC=N3)=O)=O)=O)=O)OC-Research_Area-Cancer-Solubility-DMSO : 100 mg/mL (ultrasonic)-Target-Drug-Linker Conjugates for ADC-Isoform–Pathway-Antibody-drug Conjugate/ADC Related-MCE Product type-ADC Related